SCYNEXIS (SCYX) Projected to Release Earnings on Wednesday

SCYNEXIS (NASDAQ:SCYX) is expected to issue its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.72) per share and revenue of $0.13 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

SCYNEXIS (NASDAQ:SCYX) last released its quarterly earnings data on Monday, August 10th. The company reported $0.63 earnings per share for the quarter, topping the consensus estimate of ($0.51) by $1.14. The firm had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.08 million. On average, analysts expect SCYNEXIS to post ($1.60) EPS for the current fiscal year and ($0.80) EPS for the next fiscal year.

SCYNEXIS Stock Performance

Shares of SCYX opened at $3.77 on Monday. The firm has a market cap of $37.51 million, a P/E ratio of -1.80 and a beta of 1.15. SCYNEXIS has a 52 week low of $3.53 and a 52 week high of $9.12. The firm’s 50-day simple moving average is $4.56 and its 200 day simple moving average is $5.52.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Wall Street Zen upgraded SCYNEXIS from a “strong sell” rating to a “hold” rating in a research note on Sunday, August 16th. Brookline Capital Markets reissued a “buy” rating on shares of SCYNEXIS in a report on Friday, July 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of SCYNEXIS in a report on Thursday, October 22nd. Finally, Guggenheim restated a “buy” rating and set a $33.00 price objective (up from $24.00) on shares of SCYNEXIS in a research report on Thursday, August 13th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $33.00.

About SCYNEXIS

SCYNEXIS, Inc is a biotechnology company focused on developing and commercializing innovative antifungal therapies for the treatment of serious and common fungal infections. The company’s research platform is centered on ibrexafungerp, a novel triterpenoid antifungal designed to inhibit glucan synthase, an enzyme important to the formation of fungal cell walls.

SCYNEXIS’s lead product, BREXAFEMME (ibrexafungerp tablets), is an oral antifungal approved in the United States for the treatment of vaginal yeast infections, also known as vulvovaginal candidiasis.